Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients
Romain Rouet, Jake Y. Henry, Matt D. Johansen, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants
Yanqun Wang, An Yan, Deyong Song, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Xiaoyu Zhao, Tianyi Qiu, Xiner Huang, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
Lihong Liu, Ryan G. Casner, Yicheng Guo, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2442-2455.e8
Open Access | Times Cited: 16
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies
Ohan Mazigi, David B. Langley, Jake Y. Henry, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 1
Open Access
Unlocking the potential of in silico approach in designing antibodies against SARS-CoV-2
Tasshitra R. Subramaniam, Siti Aisyah Mualif, Weng Howe Chan, et al.
Frontiers in Bioinformatics (2025) Vol. 5
Open Access
Epimaps of the SARS-CoV-2 Receptor-Binding Domain Mutational Landscape: Insights into Protein Stability, Epitope Prediction, and Antibody Binding
Eleni Pitsillou, Assam El‐Osta, Andrew Hung, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 301-301
Open Access
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
Yu Lei, Yajie Wang, Yuanchen Liu, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2
Peng Yu, Jingping Ran, Ruiqi Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
Lingyan Cui, Tingting Li, Wenhui Xue, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 900-900
Open Access | Times Cited: 4
Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
Lihong Liu, Ryan G. Casner, Yicheng Guo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 11
Passive immunotherapies for the next influenza pandemic
Daniele Focosi, Massimo Franchini, Jonathon W. Senefeld, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 3
Closed Access | Times Cited: 3
Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity
Alexandra R. Dvorscek, Craig I. McKenzie, Vera C Stäheli, et al.
Immunity (2024)
Closed Access | Times Cited: 3
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 8
Open Access | Times Cited: 2
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
Lee Tatham, Anja Kipar, Joanne Sharp, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
Widespread impact of immunoglobulin V-gene allelic polymorphisms on antibody reactivity
Meng Yuan, Ziqi Feng, Huibin Lv, et al.
Cell Reports (2023) Vol. 42, Iss. 10, pp. 113194-113194
Open Access | Times Cited: 6
Developments in treatment for middle east respiratory syndrome coronavirus (MERS-CoV)
Jaffar A. Al‐Tawfiq
Expert Review of Respiratory Medicine (2024) Vol. 18, Iss. 5, pp. 295-307
Closed Access | Times Cited: 1
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2
Cyril Planchais, I. Fernández, Benjamin Chalopin, et al.
iScience (2024) Vol. 27, Iss. 7, pp. 110354-110354
Open Access | Times Cited: 1
De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination
Thierry Le Bihan, Teresa Núñez de Villavicencio-Díaz, Chelsea Reitzel, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice
Anders Frische, Karen A. Krogfelt, Anders Fomsgaard, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 218-218
Open Access | Times Cited: 1
Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2
Xiaoyu Chu, Xinyu Ding, Yixuan Yang, et al.
Biochemical and Biophysical Research Communications (2023) Vol. 660, pp. 43-49
Open Access | Times Cited: 3
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
Tony W. Ng, Steven A. Porcelli
Journal of Cellular Immunology (2023) Vol. 5, Iss. 4, pp. 97-102
Open Access | Times Cited: 3
Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
Letícia Carrijo Masson, Carolina do Prado Servian, Vitor Hugo Jardim, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1183-1183
Open Access | Times Cited: 2
de NovoSequencing of Antibodies for Identification of Neutralizing Antibodies in Human Plasma Post SARS-CoV-2 Vaccination
Thierry Le Bihan, Teressa Nunez de Villavicencio Diaz, Chelsea Reitzel, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus
Ji Hyun Lee, Ji Woong Kim, H Lee, et al.
Virus Research (2024) Vol. 345, pp. 199383-199383
Open Access
Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence
Arman Izadi, Magdalena Godzwon, Anna Söderlund‐Strand, et al.
The Journal of Immunology (2024) Vol. 213, Iss. 5, pp. 678-689
Closed Access
Page 1 - Next Page

Scroll to top